News | May 15, 2021
Dr. Reddy's Laboratories see marginal dip in FY 2021 PAT
Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021
Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
The company also plans to register the similar range of products in the neighbouring countries.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
Subscribe To Our Newsletter & Stay Updated
